The definitive annual review of what happened, what changed, what's coming next — and what it means for your protocol.
The past twelve months have been the most consequential in the history of consumer longevity science. The field has crossed a threshold: aging is no longer treated as a single pathway to fix but as a progressive loss of coordination between biological systems — metabolic, immune, mitochondrial, and microbial. The practical consequence is that combination approaches targeting multiple hallmarks simultaneously are now the research priority, not isolated compounds.
Three developments define 2025–2026. First, the PEARL trial published its results, delivering the first substantial randomized controlled data on rapamycin in healthy humans — and the findings were nuanced. Second, the GLP-1 agonist revolution expanded far beyond weight loss, with data now showing cardiovascular protection independent of weight change, kidney benefits, and early signals in liver disease resolution. Third, and perhaps most historically significant, the FDA cleared the first human trial of epigenetic reprogramming — Life Biosciences' ER-100 gene therapy targeting retinal cells, representing the first time Yamanaka-factor-based partial reprogramming will be tested in living humans.
For individuals managing their own longevity protocols, the actionable takeaways this year are clear: exercise remains the most powerful intervention, sleep is the foundation everything else is built on, metabolic health testing (especially fasting insulin and HOMA-IR) should be standard for everyone, and the supplement landscape continues to consolidate around a smaller number of well-evidenced compounds.
The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial — a 48-week, double-blinded, randomized, placebo-controlled study — delivered its full results. Participants received either placebo, 5 mg, or 10 mg of compounded rapamycin weekly. Adverse events were similar across all groups, establishing a baseline safety profile for intermittent low-dose use. Visceral fat (the primary endpoint) did not change significantly. However, women receiving 10 mg showed meaningful improvements in lean tissue mass and self-reported pain, while 5 mg users reported improvements in emotional well-being and general health.
The PEARL trial confirmed that low-dose intermittent rapamycin is relatively safe over 48 weeks. But the efficacy signal was modest and sex-specific — far from the dramatic lifespan effects seen in mice. The compounded form used had lower bioavailability than commercial sirolimus, complicating dose interpretation. Rapamycin remains promising but is not yet validated as a human longevity drug. Read our full rapamycin review →
A landmark study published in Cell demonstrated that metformin slowed the progression of DNA methylation-based aging biomarkers in male monkeys. This provided the first robust primate evidence supporting metformin's geroprotective effects beyond its metabolic benefits. The TAME trial (Targeting Aging with Metformin) — designed to test whether metformin delays the onset of age-related diseases in 3,000 adults aged 65–79 — remains only partially funded and has not yet begun enrollment, a frustrating reality for the field.
The primate data strengthens the case for metformin, but the TAME trial's funding challenges mean we're still waiting for definitive human data in non-diabetics. For those already on metformin for diabetes, the longevity signal is encouraging. For healthy individuals, the evidence doesn't yet justify off-label use. Read our metformin analysis →
Sub-analyses from the SELECT trial (17,604 participants) revealed that semaglutide's 20% reduction in major adverse cardiovascular events was at least partially independent of weight loss — roughly one-third of the cardiovascular benefit could not be attributed to weight reduction. Additional analyses showed kidney protective effects (22% lower risk for composite kidney endpoints) and benefits that emerged rapidly, within the first six months of treatment. The ESSENCE trial further showed semaglutide resolved fatty liver inflammation in nearly 63% of patients.
GLP-1 agonists are emerging as genuine multi-system interventions, not just weight loss drugs. The weight-independent cardiovascular benefit suggests direct anti-inflammatory or metabolic mechanisms that could have longevity implications. The SELECT-LIFE extension study is now tracking all-cause mortality — the longevity community should watch this closely. Read our GLP-1 review →
The following interventions had their evidence base strengthened by new data published in the past 12 months.
The longevity field is shifting from preclinical animal models toward focused human clinical evaluations. Several key trials saw significant developments this year.
PEARL (Rapamycin) — Results published April 2025. 48-week safety data established. Modest efficacy signals, particularly for lean mass in women. Future studies will evaluate broader dose ranges. Status: Complete, results published.
TAME (Metformin) — Remains partially funded. The trial design has FDA approval but enrollment has not begun. Nir Barzilai continues fundraising efforts and has stated he believes positive evidence is mounting from observational data. Status: Seeking funding.
Life Biosciences ER-100 (Epigenetic Reprogramming) — FDA cleared IND application in January 2026. Phase 1 first-in-human trial targeting retinal cells in glaucoma and NAION patients. Uses three Yamanaka factors (Oct4, Sox2, Klf4) without the oncogenic c-Myc. Status: Phase 1 initiated.
SELECT-LIFE (Semaglutide Long-term) — Extension study following 3,439 participants from the original SELECT trial to evaluate all-cause mortality over up to 120 months. Status: Active, enrolling.
Urolithin A + Fisetin Sleep/Aging Study — NCT06990256 evaluating the combined effects of urolithin A and fisetin on sleep quality and aging biomarkers. Status: Recruiting.
Dog Aging Project (Rapamycin in Dogs) — Continues to generate data on rapamycin's effects in a large-animal model with shared environment. Preliminary signals on cardiac function being analyzed. Status: Active.
For a complete, filterable dashboard of 24 curated longevity trials, visit our Clinical Trial Tracker →
The reconceptualization of GLP-1 receptor agonists from "weight loss drugs" to potential longevity interventions is arguably the most consequential pharmaceutical development of the year. GLP-1 receptors are now known to be distributed across virtually every organ system — heart, brain, kidneys, liver — and activating them triggers cascades of anti-inflammatory and cellular repair mechanisms that directly counteract biological aging processes.
Key data points in the past 12 months: the SELECT trial confirmed that roughly one-third of semaglutide's cardiovascular benefit is independent of weight loss, suggesting direct biological mechanisms. The ESSENCE trial demonstrated fatty liver resolution in nearly 63% of patients — a condition with almost no prior effective treatments. Emerging epidemiological data from large patient registries suggests GLP-1 users show lower incidence rates for several obesity-related cancers. A 2025 Cell Metabolism study showed GLP-1 agonists reversed biological aging markers in mice across the heart, brain, and kidneys — without requiring weight loss.
The financial dimensions are staggering. The global GLP-1 market is projected to reach over $200 billion by 2033. This is no longer a niche pharmaceutical segment — it is becoming the largest drug class in history. Combination therapies pairing GLP-1s with SGLT2 inhibitors, HRT, or even rapamycin are now being explored in research settings.
GLP-1 agonists are prescription medications with significant side effects and cost ($1,000+/month without insurance). They are not appropriate for everyone. But for individuals with obesity, metabolic syndrome, cardiovascular disease, or NAFLD, the evidence now supports discussing them with a physician not just for weight management but for potential multi-system health benefits. Read our full GLP-1 evidence review →
In January 2026, the FDA cleared Life Biosciences' investigational new drug application for ER-100, a gene therapy designed to rejuvenate damaged retinal cells using partial epigenetic reprogramming. This marks the first time Yamanaka-factor-based cellular rejuvenation will be tested in living humans — a moment many in the field have been waiting for since Shinya Yamanaka's Nobel Prize-winning discovery in 2006.
The therapy uses three of the four Yamanaka factors (Oct4, Sox2, and Klf4), excluding c-Myc due to its association with tumor formation. The key innovation is a doxycycline-inducible system that gives researchers precise control over when the reprogramming factors are active — treatment can be paused or stopped if needed. ER-100 is delivered locally to the eye, limiting systemic exposure and risk.
This trial is narrowly focused on eye diseases (open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy) and is primarily assessing safety, not anti-aging efficacy. But the implications extend far beyond ophthalmology. Altos Labs, NewLimit, Retro Biosciences, and other well-funded startups are developing their own reprogramming approaches for other organ systems. If this trial establishes safety, it will open the door for broader applications.
This is a genuinely historic moment for longevity science — the first test of whether cellular age can be reversed in living humans. But it's a Phase 1 safety trial in a small number of patients, targeting a specific eye condition. Systemic anti-aging therapies based on reprogramming are likely 10–15 years away at minimum. The hype will outpace the science. Read our Yamanaka factors deep dive →
Biological age testing is becoming as routine as annual physicals. DunedinPACE has emerged as the preferred epigenetic clock for measuring the pace of aging (as opposed to a single-point age estimate), and it's increasingly being adopted by longevity clinics and research protocols as a standardized outcome measure.
In the consumer wearable space, the key trend is integration. Oura Ring, Apple Watch, Whoop, and Garmin are all converging on similar feature sets: HRV tracking, sleep staging, blood oxygen, temperature trends, and activity metrics. The differentiator is moving from hardware to software — specifically, how well each platform interprets data and provides actionable guidance. Apple Watch's sleep apnea detection feature, approved by the FDA, represents a meaningful clinical capability that could catch a condition affecting sleep quality and longevity in millions of undiagnosed users.
Continuous glucose monitors (CGMs) remain popular among longevity enthusiasts, though the evidence for their benefit in non-diabetic individuals is still limited to n=1 self-experimentation. The more impactful trend is the growing accessibility of at-home blood testing panels from companies like Function Health, InsideTracker, and direct-to-consumer lab services — making comprehensive biomarker tracking more accessible than ever.
The global anti-aging market exceeded $85 billion in 2025 and is projected to approach $120 billion by 2030. But the nature of spending is shifting. The market is no longer defined by vanity products — it's increasingly driven by therapeutics, testing, and evidence-based interventions.
Longevity-focused startups to watch include Altos Labs (backed by $3 billion in funding, focused on cellular rejuvenation), Retro Biosciences (partial reprogramming and plasma-based approaches), NewLimit (epigenetic reprogramming), and Rubedo Life Sciences (senolytic therapies planning 2026 clinical trials for skin rejuvenation). The convergence of AI and drug discovery is accelerating the identification of geroprotective compounds.
The longevity clinic market is expanding rapidly, with services ranging from Peter Attia's Early Medical practice (approximately $150,000+/year) to more accessible options like Function Health ($499/year) and Healthspan's telehealth platform. The challenge for consumers remains separating evidence-based services from marketing-driven ones. Our Longevity Practitioner Comparison covers this in detail.